English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Panoramic views of post-marketing safety profiles, such as cancer signal, of phosphodiesterase 5A (PDE5A) inhibitors have yet to be fully evaluated. Data from the FDA Adverse Event Reporting System (FAERS) concerning the timeframe between January 1 st , 2004 to 30 June 2022 was analyzed through a disproportionality study to understand the association between sildenafil, tadalafil, and vardenafil and cancer. This association was identified using the Reporting odds ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) approaches. Sildenafil associated ROR values and IC 025  ranged from 9.19 (95% CI 7.72–10.94, IC 025  2.77) for metastatic malignant melanoma to 132.23 (95% CI 95.49–183.11, IC 025  4.69) for malignant melanoma stage II. Tadalafil associated ROR and IC 025  ranged from 6.79 (95% CI 5.41–8.54, IC 025  2.27) for metastatic malignant melanoma to 180.17 (95% CI 130.11–249.50, IC 025  4.89) for malignant melanoma stage II. Vardenafil associated ROR and IC 025  ranged from 23.38 (95% CI 15.20–35.96, IC 025  2.63) for metastatic malignant melanoma to 245.77 (95% CI 154.42–391.16, IC 025  2.10) for malignant melanoma stage III. This study supports the association between sildenafil, tadalafil, and vardenafil with skin cancer signal in erectile dysfunction (ED) patients.

Skin cancer signal associated with phosphodiesterase inhibitors: gaining insight through the FDA pharmacovigilance database